Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Evotec SE's shares outstanding for the quarter that ended in Mar. 2026 was 177.6 Mil.
Evotec SE's quarterly shares outstanding
increased
from Dec. 2025 (177.5 Mil) to Mar. 2026 (177.6 Mil).
It means Evotec SEissued new shares from Dec. 2025 to Mar. 2026 .
Evotec SE's annual shares outstanding
declined
from Dec. 2024 (177.6 Mil) to Dec. 2025 (177.5 Mil).
It means Evotec SEbought back shares from Dec. 2024 to Dec. 2025 .
Evotec SE (OTCPK:EVOTF) Shares Outstanding (EOP) Explanation
A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.
Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.
Be Aware
Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.
Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.
If net earnings is less than 10%, likely to be in a highly competitive business.
Evotec SE Shares Outstanding (EOP) Related Terms
Evotec SE Shares Outstanding (EOP) Historical Data
* Premium members only.
The historical data trend for Evotec SE's Shares Outstanding (EOP) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EVOTF vs ZTS, UTHR, VTRS: Shares Outstanding (EOP) Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Evotec SE's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evotec SE Shares Outstanding (EOP) vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Evotec SE's Shares Outstanding (EOP) distribution charts can be found below:
* The bar in red indicates where Evotec SE's Shares Outstanding (EOP) falls into.
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.
Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.
What does a Shares Outstanding (EOP) of 177.6 Mil mean?
Evotec SE (EVOTF) has a Shares Outstanding (EOP) of 177.6 Mil as of Mar. 2026. The total shares a company has outstanding, at period-end. View historical data on Evotec SE and its competitors.
Is Evotec SE's Shares Outstanding (EOP) too high?
Evotec SE's current Shares Outstanding (EOP) is 177.6 Mil. Overall, Evotec SE has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evotec SE's Shares Outstanding (EOP) compare to ZTS and UTHR?
Evotec SE's Shares Outstanding (EOP) of 177.6 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Drug Manufacturers company?
A good Shares Outstanding (EOP) depends on the Drug Manufacturers industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Evotec SE and its competitors. Evotec SE's current Shares Outstanding (EOP) is 177.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evotec SE stock overvalued right now?
Based on GuruFocus' analysis, Evotec SE (EVOTF) is currently considered Possible Value Trap. The stock's GF Value™ is $10.39, compared to a current price of $6.69 — trading 35.6% below its estimated fair value. The current Shares Outstanding (EOP) is 177.6 Mil. Evotec SE's overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Evotec SE (EVOTF), the current Shares Outstanding (EOP) is 177.6 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Evotec SE (EVOTF) Overvalued in 2026?
Based on GuruFocus' analysis, Evotec SE stock appears to be undervalued.
The current stock price of $6.69 is trading 35.6% below its estimated GF Value™ of $10.39.
GuruFocus considers Evotec SE to be Possible Value Trap.
Key valuation signals for EVOTF:
Shares Outstanding (EOP): 177.6 Mil
GF Value™: $10.39 vs. price of $6.69 (35.6% below fair value)
No single metric tells the full story. See the EVOTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
62GF Score
Get the complete analysis for EVOTF
Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EVOTF has been successfully added to your 
